reviews of hers glp 1 Hims & @Hers sees strong early results from its GLP-1 weight loss program. New internal data shows users lost an average 20.9 pounds in six months, with high adherence and low Hims & Hers Health shares

Diabetes (2004) 53(1):513

Traditionally, GLP-1 medications have been prescribed at higher doses for individuals who have not seen substantial weight loss results through dieting and exercise

Two other pharmaceutical companies have their own oral GLP-1 drugs in the works: Orforglipron: Developed by Eli Lilly, its in Phase 3 clinical trials for treating type 2 diabetes and obesity, with an expected September 2025 completion

Transforma Peptides will not provide information related to research

Standard-dose protocols generally follow the same overall concept used in FDA-approved GLP-1 treatment: start low, increase gradually, and adjust based on response and side effects

But the Centers for Medicare & Medicaid Services (CMS) has the authority to test coverage changes through Center for Medicare and Medicaid Innovation (CMMI) models and other statutory demonstration authorities